mTOR inhibition and its effect on cancer in transplantation

被引：36

作者：

Andrassy, J ^{[1
]}

Graeb, C ^{[1
]}

Rentsch, M ^{[1
]}

Jauch, KW ^{[1
]}

Guba, M ^{[1
]}

机构：

[1] Univ Munich, Univ Hosp, Dept Surg, Klinikum Grosshadern, D-8000 Munich, Germany

来源：

TRANSPLANTATION | 2005年 / 80卷 / 01期

关键词：

transplantation; mTOR inhibitor; cancer;

D O I：

10.1097/01.tp.0000186912.23630.85

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A considerable amount of data indicates that transplanted patients are at increased risk for de novo and recurrent cancer. Treatment of this population is difficult. It remains unclear if the immunosuppressive therapy should be continued, tapered or even stopped or if immunosuppressive drugs with antiproliferative properties have beneficial effects in this situation. In various models, mTOR-inhibitors were shown to have immunosuppressive and anti-tumor effects. Here, we have reviewed the current literature trying to clarify if mTOR-inhibition brings advantages for the transplanted patients suffering from tumors.

引用

页码：S171 / S174

页数：4

共 51 条

[1] Identification of TOR signaling complexes: more TORC for the cell growth engine [J].

Abraham, RT .

CELL, 2002, 111 (01) :9-12

[2] AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].

Altomare, DA ;

Wang, HQ ;

Skele, KL ;

De Rienzo, A ;

Klein-Szanto, AJ ;

Godwin, AK ;

Testa, JR .

ONCOGENE, 2004, 23 (34) :5853-5857

[3] Frequent activation of AKT2 kinase in human pancreatic carcinomas (vol 87, pg 470, 2002) [J].

Altomare, DA ;

Tanno, S ;

De Rienzo, A ;

Klein-Szanto, A ;

Tanno, S ;

Skele, KL ;

Hoffman, JP ;

Testa, JR .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (01) :470-476

[4] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[5] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[6] Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer [J].

Boffa, DJ ;

Luan, FL ;

Thomas, D ;

Yang, H ;

Sharma, VK ;

Lagman, M ;

Suthanthiran, M .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :293-300

[7] Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells [J].

Boulay, A ;

Zumstein-Mecker, S ;

Stephan, C ;

Beuvink, I ;

Zilbermann, F ;

Haller, R ;

Tobler, S ;

Heusser, C ;

O'Reilly, T ;

Stolz, B ;

Marti, A ;

Thomas, G ;

Lane, HA .

CANCER RESEARCH, 2004, 64 (01) :252-261

[8] A MAMMALIAN PROTEIN TARGETED BY G1-ARRESTING RAPAMYCIN-RECEPTOR COMPLEX [J].

BROWN, EJ ;

ALBERS, MW ;

SHIN, TB ;

ICHIKAWA, K ;

KEITH, CT ;

LANE, WS ;

SCHREIBER, SL .

NATURE, 1994, 369 (6483) :756-758

[9] Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin [J].

Brunn, GJ ;

Hudson, CC ;

Sekulic, A ;

Williams, JM ;

Hosoi, H ;

Houghton, PJ ;

Lawrence, JC ;

Abraham, RT .

SCIENCE, 1997, 277 (5322) :99-101

[10] Inhibition of the phosphatidylinositol 3-kinase/p70(S6)-kinase pathway induces B16 melanoma cell differentiation [J].

Busca, R ;

Bertolotto, C ;

Ortonne, JP ;

Ballotti, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (50) :31824-31830

← 1 2 3 4 5 6 →